Allworth Financial LP Sells 213 Shares of Moderna, Inc. (NASDAQ:MRNA)

Allworth Financial LP trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 11.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,620 shares of the company’s stock after selling 213 shares during the period. Allworth Financial LP’s holdings in Moderna were worth $108,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after purchasing an additional 5,129,800 shares during the last quarter. Capital World Investors raised its holdings in shares of Moderna by 0.5% in the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after purchasing an additional 18,728 shares during the last quarter. Mawer Investment Management Ltd. raised its holdings in shares of Moderna by 6.7% in the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after purchasing an additional 120,621 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Moderna by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after purchasing an additional 29,566 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. raised its holdings in shares of Moderna by 156.9% in the first quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock valued at $79,044,000 after purchasing an additional 453,004 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on MRNA. Jefferies Financial Group lowered their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. Barclays decreased their price objective on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a report on Monday, September 16th. Piper Sandler decreased their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and decreased their price objective for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Finally, Sanford C. Bernstein began coverage on shares of Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective for the company. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $94.65.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $54.36 on Friday. The company has a 50 day moving average of $65.70 and a 200 day moving average of $101.69. The stock has a market cap of $20.83 billion, a P/E ratio of -3.47 and a beta of 1.66. Moderna, Inc. has a 12 month low of $52.26 and a 12 month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the previous year, the company earned ($3.62) earnings per share. Moderna’s revenue for the quarter was down 29.9% on a year-over-year basis. As a group, sell-side analysts forecast that Moderna, Inc. will post -9.88 EPS for the current fiscal year.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,184 shares of company stock valued at $238,531 in the last quarter. Corporate insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.